AlfaEx

CompletedPhase NA

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

The Role of Glucagon-like Peptide-1 Receptor Signalling in the Glucose-lowering Effect of Increased Carbohydrate Content in the Distal Small Intestines After Meal Ingestion in Patients With Type 2 Diabetes

Lead sponsor

University Hospital, Gentofte, Copenhagen

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•BMI 23-35

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03241303

Org study IDH-17007893

Timeline

Milestones

Study start2017-08-01actual

Study first posted2017-08-07actual

Primary completion2018-01-01actual

Study completion2018-01-01actual

Last update posted2020-03-26actual

Assets

Investigational agents

Avexitide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes for at least three months (diagnosed according to the criteria of the World Health Organization (WHO)) treated with metformin monotherapy

•Caucasian ethnicity

•Normal haemoglobin

•Age >18 years

•BMI >23 kg/m2 and <35 kg/m2

•Informed and written consent

Exclusion criteria

•Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >2 times normal values) or history of hepatobiliary disorder

•Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery

•Reduced kidney function or nephropathy (estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 (based on serum creatinine) and/or albuminuria

•Treatment with medicine that cannot be paused for 12 hours

•Intake of antibiotics two months prior to study

•Treatment with glucose-lowering drugs other than metformin

•Hypo- and hyperthyroidism

•Treatment with oral anticoagulants

•Active or recent malignant disease

•Any treatment or condition requiring acute or sub-acute medical or surgical intervention

•Lack of effective birth control in premenopausal women

•Positive pregnancy test on study days in premenopausal women

•Pregnancy

•Women who are breastfeeding

•Any condition considered incompatible with participation by the investigators

•If the subjects receive any antibiotic treatment while included in the study they will be excluded

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.